Ignite Creation Date:
2024-05-06 @ 3:06 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04524689
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-17
First Post:
2020-08-20
Brief Title:
Tusamitamab Ravtansine SAR408701 in Combination With Pembrolizumab and Tusamitamab Ravtansine SAR408701 in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
Sponsor:
Sanofi
Organization:
Sanofi
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-10-26
Start Date Type:
ACTUAL
Primary Completion Date:
2024-03-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2020-08-20
First Submit QC Date:
August 20 2020
Study First Post Date:
2020-08-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-16
Last Update Post Date:
2024-05-17
Last Update Post Date Type:
ACTUAL